Work Productivity and Healthcare Resource Utilization Outcomes for Patients on Etanercept for Moderate-to-Severe Plaque Psoriasis

Ronald Vender (), Charles Lynde, Vincent Ho, Dina Chau and Melanie Poulin-Costello

Applied Health Economics and Health Policy, 2012, vol. 10, issue 5, 343-353

Abstract: Background: Data investigating the effect of etanercept on work productivity and healthcare resource utilization in Canadian patients in a clinical setting is limited. Objective: The aim of the study was to describe work productivity and healthcare resource utilization in patients with psoriasis prescribed etanercept. Methods: A 12-month, phase IV, non-randomized, multicentre, open-label, single-arm prospective trial of patients with moderate-to-severe plaque psoriasis was conducted between March 2006 and July 2009 in 37 community dermatology practice sites across Canada. A total of 246 patients were enrolled. Major eligibility criteria: ≥18 years of age; diagnosis of moderate-to-severe plaque psoriasis at baseline (Physician Global Assessment [PGA] ≥3, scale 0–5); able to start etanercept therapy as per product monograph. Patients received etanercept (Enbrel®) 50 mg subcutaneously twice weekly for 3 months, then 50 mg once weekly for 9 months. Outcomes were measured by average change and average percent change from baseline at months 3, 6, 9 and 12 on the Work Productivity and Activity Im-pairment (WPAI) and Healthcare Resource Utilization (HRU) questionnaires. Results: The mean degree of impairment while working ± standard deviation (SD) in the total population decreased from 22.7% ±23.2 at baseline to 6.6% ±14 after 3 months of treatment (p > 0.0001). From baseline to 3 months, overall work impairment± SD decreased from 23.7%±23.7 to 8.3%±16.5 (p > 0.0001) and mean activity impairment outside the workplace decreased from 31.4%±26.4 to 12.9%±22.4 (p>0.0001). All these improvements were sustained to month 12. Other variables that decreased on average from baseline to month 3, sustained to month 12, included physician office visits (2.3/month±3.5 at baseline to 0.6/month± 1.0 at month 3; p>0.0002), hours of assistance required of family and friends to assist with psoriasis (1.1 hours/week ±2.6 at baseline to 0.3 hours/week ± 1.5 at month 3; p=0.0002) and amount of time spent on activities to manage psoriasis (5.5 hours/week±6.2 at baseline to 1.9 hours/week±3.7 at month 3; p>0.0001). Also, the amount of out-of-pocket expenses to manage psoriasis decreased from $Can94.9/month±331.6 at baseline to $Can35.7±69.1 at month 12 (p=0.0153). Conclusions: Use of etanercept in Canadian patients in a clinical practice setting correlated with improvement in work productivity and reduced HRU after 3 months of treatment, and improvement was sustained up to 12 months. Copyright Springer International Publishing AG 2012

Date: 2012
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
http://hdl.handle.net/10.1007/BF03261868 (text/html)
Access to full text is restricted to subscribers.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:aphecp:v:10:y:2012:i:5:p:343-353

Ordering information: This journal article can be ordered from
http://www.springer.com/economics/journal/40258

DOI: 10.1007/BF03261868

Access Statistics for this article

Applied Health Economics and Health Policy is currently edited by Timothy Wrightson

More articles in Applied Health Economics and Health Policy from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().